Company restructures business into three distinct divisions that include in
vitro diagnostics, cancer therapeutics and China-based integrated
TUSTIN, Calif., Oct. 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with major operations in China and the US, today announced it has restructured its business into three distinct divisions to better reflect the Company's operational focus on becoming a world-class, diversified pharmaceutical company.
The new divisions include an In Vitro Diagnostics (IVD) division specifically focused on accelerating AMDL's market launch for the AMDL-ELISA DR-70(R) (FDP) cancer test; a Cancer Therapeutics division specifically focused on accelerating research for its Combination Immunogene Therapy (CIT) technology; and a China-based Integrated Pharmaceuticals division focused on the continued manufacturing, sales and distribution of AMDL's broad range of generic, specialty and branded pharmaceutical products.
AMDL will continue to execute its 2008 business plan with a focus on
achieving its stated financial target of a 100% increase in sales over
2007. Additionally, under this new operational structure, AMDL will
aggressively work to:
-- Establish the IVD division for DR-70 with a structural platform for
funding the division through a potential joint-venture partnership(s)
or selling the division as a stand-alone business;
-- Establish the Cancer Therapeutics division with a structural platform
for funding the division through a potential joint-venture
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved